Kynexis

Kynexis is advancing the potential precision medicine for the treatment of cognitive impairment associated with schizophrenia (CIAS).

Health and bio

TIMELINE · MONEY RAISED

Kynexis | 1310 days from website to first raise on record

@KynexisTx·Raised $113M in 1 sourced round·2 signals before the first raise

Money raised, round by round (amounts linked to their source). Pins are dated signals; hover the icons for dates.

Funding rounds

1. August 19, 2026
   Series A · $112.57M
   NNovartis Venture Fund (lead), FForbion Capital Partners, SSunstone Life Science Ventures, YYsios Capital
   Source: fundraisingfox.com
2. May 24, 2023
   X account created
3. January 17, 2023
   Website created

Team

• AL
  Abi Liddle Chief Operations Officer
• JW
  Jens Wendland Chief Medical Officer
• KB
  Kees Been Chief Executive Officer
• NS
  Neil Swami CBO

Investors

• FForbion Capital Partners
• NNovartis Venture Fundlead investor
• SSunstone Life Science Ventures
• YYsios Capital

Companies like Kynexis

• AA2 Biotherapeutics$80M Series B+ · Jan 2025
• KK36 Therapeutics$70M Series B+ · Jun 2023
• FFrontier MedicinesSeries B+ · Aug 2025
• IImageneSeed · May 2022
• WWobble Genomics$1.66M Seed · Sep 2021
• WWaiv$33M Series A · Apr 2026

Other companies backed by Novartis Venture Fund

• FFore Biotherapeutics$67.4M Series B+ · Jul 2026
• FFlare Therapeutics$85M Series B+ · Jun 2026
• MMediar Therapeutics$76M Series B+ · Jan 2026
• FFoRx Therapeutics$50M Series A · Dec 2025
• NNRG Therapeutics$67M Series B+ · Sep 2025
• SSplice Bio$140M Series B+ · Jun 2025

Novartis Venture Fund portfolio →